CLINICAL TRIAL SERVICES
The Buffalo Neuroimaging Analysis Center (BNAC) is a dedicated research center that has expertise in clinical trials using preclinical chronic progressive models of multiple sclerosis (MS).
In contrast to experimental autoimmune encephalomyelitis (EAE), the Theiler Murine Encephalomyelitis Virus (TMEV) model is an axonal viral infection-mediated demyelinating disease represented by biphasic relapsing and progressive disease course, like MS. TMEV is characterized by an initial acute demyelination that is followed by prolonged inflammation of the axons resulting in progressively adverse demyelination and axonal loss. TMEV-infected animals exhibit progressive motor deterioration which is associated with a development of the brain and spinal cord atrophy.
MS therapies use small molecules designed to target CNS infiltratory inflammatory cells with higher metabolic rate, aim to restrict such sporadic immune activity during MS relapses. TMEV is a demyelinating disease model in which direct immunization is not the primary driver. TMEV is a protracted viral axonal infection mediated demyelinating disease in mice for modeling MS. In its biphasic disease timeline, the inability of the SJL mice to completely eliminate inflammation within the axons leads to the initial acute demyelination and is followed by prolonged inflammation of the axons resulting in progressively adverse demyelination.
Because of striking similarities with progressive MS disease course and its pathology, the TMEV has been increasingly used to test efficacy of DMTs. BNAC has recently conducted several preclinical trials with currently FDA approved DMTs, as well as those in various stages of preclinical and clinical development, using the TMEV model of MS.
FEATURED TMEV CLINICAL TRIALS IN MS
- Zivadinov R, Schweser F, Dwyer MG, Pol S. Detection of Monocyte/Macrophage and Microglia Activation in the TMEV Model of Chronic Demyelination Using USPIO-Enhanced Ultrahigh-Field Imaging. J Neuroimaging 2020.[Open article]
- Pol S, Dhanraj R, Zivadinov R (2020) Bruton tyrosine kinase inhibitor suppresses disease progression in Thieler’s Murine Enchephalomyelitis Virus mouse model of multiple sclerosis. 8th Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 September 11-13:P0302.
- Zivadinov R, Schweser F, Dwyer M, Pol S (2020) Effect of anti-muCD52 antibody on brain and spinal cord imaging markers of neurodegeneration, microglia, and macrophage activation in the Theiler’s Murine Encephalomyelitis Virus model of chronic demyelination. 72nd Annual Meeting of the American Academy of Neurology, Toronto, Canada April 29:P2:013 [Open article]
CONTACT OUR TEAM TODAY
Part of BNAC’s mission is to help share our tools and experience with our colleagues and other industry partners. If you need help with managing a preclinical trial using TMEV model, please reach out to discuss how we can assist. Our group brings decades of experience and expertise to every collaborative study and service partnership.